WASHINGTON, Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET.
Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com.
Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call.
An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call.
Upcoming Investor Events
Additionally, The Company announced that its executive management team will participate in upcoming investor conferences.
A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website. Specific presentation times will be posted on the website as they become available.
About Evolent
Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting https://ir.evolent.com.
Contacts:
Seth R. Frank
Vice President, Investor Relations
Evolent
This email address is being protected from spambots. You need JavaScript enabled to view it.
571-895-3919 (W)
| Last Trade: | US$9.65 |
| Daily Change: | 0.01 0.10 |
| Daily Volume: | 1,317,860 |
| Market Cap: | US$1.120B |
August 07, 2025 May 08, 2025 April 22, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
